Substituted pyrazoles as p38 kinase inhibitors

A compound, tautomer or pharmaceutically acceptable salt of formula IB:

• wherein:
• R1 is hydrogen;
• R2 is cyclohexyl optionally substituted with alkylamino or alkylaminoalkyl;
• R3 is pyridinyl or pyrimidinyl optionally substituted with one or more substituents individually selected from the group consisting of hydrogen, alkylsulfonyl, alkylthio, amino, alkylamino, arylalkylamino, alkoxy, haloaryloxy and haloarylamino;
• and
• R4 is phenyl optionally substituted with one or more substituents individually selected from the group consisting of halo, haloalkyl, haloalkoxy, alkoxy, cyano, hydroxyl, alkyl, alkenyl and alkynyl.